Icahn Says Epic Herbalife Battle With Ackman Was `A Good Fight'
(Bloomberg) -- Carl Icahn said he harbors no ill will toward fellow billionaire investor Bill Ackman after his rival bowed out of their five-year fight over Herbalife Ltd.
Any wounded feelings on Icahn's part may have been eased by what he said was a $1 billion return on his investment -- at least on paper. Ackman has almost entirely exited his short position in the nutritional-supplements company, a person familiar with the matter said Wednesday.
“I enjoy a good fight, especially when I win,” Icahn said Thursday in an interview on CNBC.
Icahn even thanked Ackman for alerting him to the stock in the first place by taking a $1 billion short position in December 2012.
“The company really is great and Bill Ackman had the wrong idea on it,” Icahn said.
Icahn, who has defended Herbalife's multilevel-marketing model and publicly assailed Ackman on stages, television, the internet and in documentaries, is now the company's biggest holder with about 26 percent, according to data compiled by Bloomberg. The two first came to blows over the stock during a CNBC phone-in discussion in 2013.
That's all water under the bridge now, according to Icahn.
“I thought it was a classy thing. He called me up yesterday and congratulated me,” he said.
To contact the reporter on this story: Scott Deveau in New York at sdeveau2@bloomberg.net.
To contact the editors responsible for this story: Elizabeth Fournier at efournier5@bloomberg.net, Michael Hytha
©2018 Bloomberg L.P.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.